Assessment of Pancreas Safety in the Development Program of Once Weekly GLP-1 Receptor Agonist Dulaglutide
- Received May 5, 2016.
- Accepted February 5, 2017.
- Published March 10, 2017.
Copyright & Usage
© 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
- Michael A. Nauck1,
- Jean-Louis Frossard2,
- Jamie S. Barkin3,
- Greg Anglin4,
- Ingrid E. Hensley5,
- Kristine D. Harper5 and
- Zvonko Milicevic6⇑
- 1Division of Diabetology, Medical Department I, St. Josef-Hospital (Ruhr-Universität Bochum) Bochum, Germany
- 2Division of Gastroenterology, University Hospitals and Faculty of Medicine, Geneva, Switzerland
- 3Department of Medicine, Division of Gastroenterology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL
- 4Eli Lilly Canada Inc., Toronto, ON, Canada
- 5Eli Lilly and Company, Indianapolis, IN
- 6Eli Lilly and Company, Vienna, Austria
- Corresponding author: Zvonko Milicevic, .